Massive data dive reveals how SMA drugs perform outside the lab
NCT ID NCT07403214
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study analyzed health records of nearly 5,000 people with spinal muscular atrophy (SMA) to see how well three approved treatments work in everyday medical practice. Researchers looked at complications, medical equipment use, and hospital visits before and after starting each therapy. The goal was to understand real-world treatment patterns and outcomes, not to test a new drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCULAR ATROPHY, SPINAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nationwide registry unlock the secrets of adult spinal muscular atrophy?
- Can a spinal injection safely slow spinal muscular atrophy? a real-world study in korea seeks answers.
- New drug BIIB115 aims to build on gene therapy for spinal muscular atrophy
- New hope for SMA babies: boosting gene therapy with a Follow-Up drug
- Real-World data reveals treatment patterns for kids with SMA
- Higher doses of SMA drug tested for Long-Term safety